Sohonos

$4,917.91

fibrodysplasia ossificans progressiva (FOP). The medicine is indicated for female patients aged 8 years and older, and male patients aged 10 years and older1.

Sohonos (palovarotene) is approved by the FDA in the USA2.

What is Sohonos (palovarotene) for?

Sohonos (palovarotene) is indicated for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 8 and up (female) or 10 and up (male)[1].

Sohonos is available as capsules (1, 1.5, 2.5, 5, and 10 mg)[1].

How does  Sohonos (palovarotene) work?

The active ingredient in Sohonos is palovarotene, which is a retinoid. It connects to specific sites, known as retinoic acid receptors (gamma), in cells related to bone formation. When palovarotene links up with these sites, it activates mechanisms that slow down bone growth, potentially easing the symptoms of FOP[3].

Where has Sohonos (palovarotene) been approved?

Sohonos (palovarotene) is currently approved by the FDA in the USA[2]. The EMA in Europe has refused Sohonos’s application for marketing authorization[3].